Search Results - "Kwekkeboom, D"

Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Öberg, K, Knigge, U, Kwekkeboom, D, Perren, A

Get full text

ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors by Falconi, M, Eriksson, B, Kaltsas, G, Bartsch, D K, Capdevila, J, Caplin, M, Kos-Kudla, B, Kwekkeboom, D, Rindi, G, Klöppel, G, Reed, N, Kianmanesh, R, Jensen, R T

Get more information

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours by Zaknun, John J., Bodei, L., Mueller-Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O’Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., Kwekkeboom, D. J.

“…Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy involving the systemic administration of a radiolabelled peptide…”
Get full text

Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors by Bodei, L., Kidd, M., Modlin, I. M., Severi, S., Drozdov, I., Nicolini, S., Kwekkeboom, D. J., Krenning, E. P., Baum, R. P., Paganelli, G.

“…Background Peptide receptor radionuclide therapy (PRRT) is an effective method for treating neuroendocrine tumors (NETs). It is limited, however, in the…”
Get full text

Lutetium-labelled peptides for therapy of neuroendocrine tumours by Kam, B. L. R., Teunissen, J. J. M., Krenning, E. P., de Herder, W. W., Khan, S., van Vliet, E. I., Kwekkeboom, D. J.

“…Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine…”
Get full text

Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours by Yadegarfar, G, Friend, L, Jones, L, Plum, L M, Ardill, J, Taal, B, Larsson, G, Jeziorski, K, Kwekkeboom, D, Ramage, J K

“…Background: Quality of life is an important end point in clinical trials, yet there are few quality of life questionnaires for neuroendocrine tumours. Methods:…”
Get full text

Improved Control of Severe Hypoglycemia in Patients with Malignant Insulinomas by Peptide Receptor Radionuclide Therapy by van Schaik, E, van Vliet, E. I, Feelders, R. A, Krenning, E. P, Khan, S, Kamp, K, Valkema, R, van Nederveen, F. H, Teunissen, J. J. M, Kwekkeboom, D. J, de Herder, W. W

“…Context: Insulinomas are relatively rare neuroendocrine tumors of the pancreas. Only 10% are considered malignant. Control of insulin hypersecretion and…”
Get full text

Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Öberg, K., Hellman, P., Kwekkeboom, D., Jelic, S.

“…The annual incidence of lung neuroendocrine tumour has been reported to be 1.35/100 000/year and the overall age adjusted incidence for thymic carcinoid…”
Get full text

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate by KWEKKEBOOM, D. J, BAKKER, W. H, ERION, J. L, KRENNING, E. P, KAM, B. L, TEUNISSEN, J. J. M, KOOIJ, P. P. M, HERDER, W. W, FEELDERS, R. A, EIJCK, C. H. J, JONG, M, SRINIVASAN, A

“…Medical treatment and chemotherapy are seldom successful in achieving objective tumour reduction in patients with metastatic neuroendocrine tumours. Treatment…”
Get full text

Peptide Receptor Imaging and Therapy by Kwekkeboom, Dik, Krenning, Eric P, de Jong, Marion

“…This article reviews the results of somatostatin receptor imaging (SRI) in patients with somatostatin receptor-positive neuroendocrine tumors, such as…”
Get full text

Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours by Bodei, L., Mueller-Brand, J., Baum, R. P., Pavel, M. E., Hörsch, D., O’Dorisio, M. S., O’Dorisio, T. M., Howe, J. R., Cremonesi, M., Kwekkeboom, D. J., Zaknun, J. J.

Get full text

Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? by Esser, J P, Krenning, E P, Teunissen, J J M, Kooij, P P M, van Gameren, A L H, Bakker, W H, Kwekkeboom, D J

“…Patients with somatostatin receptor subtype 2-positive metastasised neuroendocrine tumours can be treated with [(177)Lu-DOTA(0),Tyr(3)]octreotate. Some use…”
Get full text

SP-0570: Neuroendocrine tumours - personalised diagnosis and treatment using radiolabelled peptides by Baum, R.P, Strosberg, J, Wolin, E, Chasen, B, Kulke, M, Bushnell, D, Caplin, M, Hobday, T, Hendifar, A, Oberg, K, Lopera Sierra, M, Kwekkeboom, D, Ruszniewsk, P, Krenning, E, Mittra, E

Get full text

6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial by Strosberg, J, Wolin, E, Chasen, B, Kulke, M, Bushnell, D, Caplin, M, Baum, R.P, Mittra, E, Hobday, T, Hendifar, A, Oberg, K, Lopera Sierra, M, Ruszniewski, P, Kwekkeboom, D

Get full text

Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy by Krenning, E. P., de Jong, M., Kooij, P. P. M., Breeman, W. A. P., Bakker, W. H., de Herder, W. W., van Eijck, C. H. J., Kwekkeboom, D. J., Jamar, F., Pauwels, S., Valkema, R.

“…Background: Peptide receptor scintigraphy with the radioactive somatostatin analogue, [111In-DTPA0]octreotide, is a sensitive and specific technique to show in…”
Get full text

5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients by van Dijk, S.C, de Herder, W.W, Kwekkeboom, D.J, Zillikens, M.C, Feelders, R.A, van Schaik, R.H.N, van Driel, M, van Leeuwen, J.P.T.M

“…Abstract In patients with a carcinoid syndrome and neuroendocrine tumors of the digestive tract (carcinoids), elevated circulating serotonin…”
Get full text

The peripheral blood compartment in patients with Graves' disease: activated T lymphocytes and increased transitional and pre‐naive mature B lymphocytes by Van der Weerd, K., Van Hagen, P. M., Schrijver, B., Kwekkeboom, D. J., De Herder, W. W., Ten Broek, M. R. J., Postema, P. T. E., Van Dongen, J. J. M., Staal, F. J. T., Dik, W. A.

“…Summary Graves' disease (GD) is an autoimmune disease that involves aberrant B and T lymphocyte responses. Detailed knowledge about lymphocyte subpopulation…”
Get full text

Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status by Bodei, L., Kidd, M., Modlin, I. M., Prasad, V., Severi, S., Ambrosini, V., Kwekkeboom, D. J., Krenning, E. P., Baum, R. P., Paganelli, G., Drozdov, I.

“…Purpose Precise determination of neuroendocrine tumor (NET) disease status and response to therapy remains a rate-limiting concern for disease management. This…”
Get full text

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients by Krenning, E P, Kwekkeboom, D J, Bakker, W H, Breeman, W A, Kooij, P P, Oei, H Y, van Hagen, M, Postema, P T, de Jong, M, Reubi, J C

“…Various tumours, classically specified as either neuroendocrine or non-neuroendocrine, contain high numbers of somatostatin receptors, which enable in vivo…”
Get full text

Well-differentiated gastric tumors/carcinomas by Ruszniewski, Philippe, Delle Fave, Gianfranco, Cadiot, Guillaume, Komminoth, Paul, Chung, Daniel, Kos-Kudla, Beata, Kianmanesh, Reza, Hochhauser, David, Arnold, Rudolf, Ahlman, Hakan, Pauwels, Stanislas, Kwekkeboom, Dik J, Rindi, Guido

Get more information